Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Meridia (sibutramine hydrochloride) capsule

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – August 2010

Summary View

 

CONTRAINDICATIONS

Meridia is contraindicated in patients:
  • with a history of coronary artery disease (e.g., angina, history of myocardial infarction), congestive heart failure, tachycardia, peripheral arterial occlusive disease, arrhythmia or cerebrovascular disease (stroke or transient ischemic attack (TIA).
  • with inadequately controlled hypertension > 145/90 mm Hg.
  • over 65 years of age.
  • receiving monoamine oxidase inhibitors (MAOIs)
  • with hypersensitivity to sibutramine or any of the inactive ingredients of Meridia.
  • who have a major eating disorder (anorexia nervosa or bulimia nervosa).
  • taking other centrally acting weight loss drugs.

WARNINGS

Concomitant Cardiovascular Disease
  • Due to an increased risk of heart attack and stroke in patients with cardiovascular disease, MERIDIA should not be used in patients with a history of coronary artery disease, congestive heart failure, arrhythmias, or stroke

PRECAUTIONS 

Geriatric Use
  • Clinical studies of sibutramine did not include sufficient numbers of patients over 65 years of age. Sibutramine is contraindicated in this group of patients.
-
-